Metropolis Healthcare Limited has informed the Exchange about Investor Presentation
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported FY25 revenue of ₹1,331 Cr (+12% YoY) with normalized EBITDA of ₹325 Cr (+14% YoY) and normalized PAT of ₹161 Cr (+26% YoY). Q4FY25 revenue grew 10% YoY to ₹345 Cr, but adjusted EBITDA rose only 5% YoY to ₹84 Cr, with the company flagging NIL margin contribution from Core Diagnostics, accelerated expansion costs, and weak February revenues as pressures. Reported FY25 PAT was hit by ~₹21 Cr of one-off expenses, mostly tied to 3 acquisitions done in Q4FY25 plus legal/professional fees for tax cases. B2C remained the growth engine at +17% YoY (₹735 Cr), with TruHealth up 24% and Specialty up 13%; the network expanded to 210 labs and 4,536 service centres across ~750 towns. Under its Metropolis 3.0 strategy, the company has guided for a mid-teen revenue CAGR from FY23 to FY26 and aims to return to pre-Covid margin levels via bolt-on acquisitions and digital transformation.
Investors may view the Q4 margin softness as a near-term concern, but the double-digit revenue growth, strong B2C momentum, and clear multi-year margin and acquisition roadmap suggest management remains confident in the FY26 recovery path. Watch for integration progress on the 3 Q4 acquisitions and whether margin trajectory improves as expansion costs normalize.